Cancer52 submitted a response on the National Institute for Health and Care Excellence (NICE) consultation on proposed changes to its methods and processes for including NICE technology appraisal recommendations in guidelines.
Cancer52’s response welcomed principles to align and incorporate but raises concerns about an integration approach especially as many treatments for rare and less common cancers would likely fall within the scope of criteria for integration.
The consultation closed on 5th April 2024 and further information can be found on the NICE website.
コメント